Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma

Polycomb repressive complex 2 (PRC2) components, EZH2 and its homolog EZH1, and PI3K/Akt signaling pathway are focal points as therapeutic targets for multiple myeloma. However, the exact crosstalk between their downstream targets remains unclear. We herein elucidated some epigenetic interactions fo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Rizk, Mohamed, Rizq, Ola, Oshima, Motohiko, Nakajima‐Takagi, Yaeko, Koide, Shuhei, Saraya, Atsunori, Isshiki, Yusuke, Chiba, Tetsuhiro, Yamazaki, Satoshi, Ma, Anqi, Jin, Jian, Iwama, Atsushi, Mimura, Naoya
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2019
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6890440/
https://ncbi.nlm.nih.gov/pubmed/31571328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14207
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi